logo-loader
RNS
viewHikma Pharmaceuticals Plc

Block listing Interim Review

/**/ link{ color: blue }visited{ color: purple } .i{size:595.3pt 841.9pt;margin:19.85pt 63.7pt 44.95pt 49.65pt;}div.i{}p.ds{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 42.55pt}span.dq{font-family: "Arial","sans-serif";color:black}p.dt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 42.55pt; text-align: center}span.do{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.du{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-left:42.55pt}span.dm{font-size:10.0pt; font-family:"Arial","sans-serif";color:black}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}span.dk{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black} table.dv{width:479.4pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.di{width:47.78%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm}td.dg{width:52.22%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}p.dx{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:1.65pt}td.df{width:47.78%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.de{width:52.22%;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.dd{width:37.62%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.dc{width:10.16%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.da{width:23.08%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} p.dy{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:3.5pt}td.cz{width:8.7%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cy{width:20.44%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dz{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:1.65pt;text-align:justify}span.cw{font-size:10.0pt;font-family: "Arial","sans-serif";color:black}span.cu{font-size:10.0pt;font-family:"Arial","sans-serif"}span.cv{color:black}td.ct{border:none}table.ea{width:17.0cm;border-collapse:collapse;border:none}td.cr{width:47.14%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.cq{width:52.86%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.cp{width:47.14%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.co{width:52.86%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.eb{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.cm{font-family:"Arial","sans-serif";color:black}span.ck{font-family:"Arial","sans-serif"; color:black}table.ec{width:494.0pt;margin-left:-5.4pt;border-collapse:collapse;border:none}tr.ch{height:12.75pt}td.ci{width:483.2pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}p.ed{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center} tr.cb{height:25.5pt}td.cg{width:65.2pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}td.cf{width:50.2pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}td.ce{width:62.2pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}td.cd{width:94.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}td.cc{width:168.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}td.bz{width:65.2pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}p.ee{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: right}td.by{width:50.2pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bx{width:62.2pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt} td.bw{width:94.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bv{width:168.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}span.bt{font-family:"Arial","sans-serif";display:none}span.bs{font-family:"Arial","sans-serif"}table.ef{width:502.1pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.br{width:491.3pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bq{width:68.15pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bp{width:52.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bo{width:62.6pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bn{width:89.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt} td.bm{width:175.7pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bl{width:68.15pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bk{width:52.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bj{width:62.6pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bi{width:89.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.bh{width:175.7pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}table.eg{width:508.65pt;margin-left:-5.4pt;border-collapse:collapse;border:none}tr.be{height:14.0pt}td.bf{width:497.85pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:14.0pt}td.bc{width:65.5pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:14.0pt} p.eh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}td.bb{width:60.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:14.0pt}td.ba{width:60.1pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:14.0pt}td.az{width:88.4pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:14.0pt}td.ay{width:180.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:14.0pt}p.ei{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.aw{font-family:"Arial","sans-serif"; display:none}table.ej{width:507.65pt;margin-left:-5.4pt;border-collapse:collapse}tr.ap{height:26.4pt}td.au{width:65.5pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:26.4pt} td.at{width:60.05pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:26.4pt}td.as{width:60.1pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:26.4pt}td.ar{width:88.4pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:26.4pt}td.aq{width:179.6pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:26.4pt}tr.aj{height:13.2pt}td.ao{width:65.5pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}td.an{width:60.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}td.am{width:60.1pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}td.al{width:88.4pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}td.ak{width:179.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt} td.ai{width:179.6pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}tr.ac{height:16.2pt}td.ah{width:65.5pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:16.2pt}td.ag{width:60.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:16.2pt}td.af{width:60.1pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:16.2pt}td.ae{width:88.4pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:16.2pt}td.ad{width:179.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:16.2pt}table.ek{width:501.55pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.aa{width:490.75pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.z{width:65.55pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt} td.y{width:53.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.w{width:60.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}span.x{font-size:10.0pt; font-family:"Arial","sans-serif"}td.v{width:88.45pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.u{width:180.45pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.t{width:65.55pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}td.s{width:53.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}td.r{width:88.45pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}td.q{width:180.45pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:13.2pt}tr.k{height:6.25pt} td.p{width:65.55pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:6.25pt}td.o{width:53.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:6.25pt}td.n{width:60.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:6.25pt}td.m{width:88.45pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:6.25pt}td.l{width:180.45pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:6.25pt} /**/
RNS Number : 3935O
Hikma Pharmaceuticals Plc
01 October 2019
 

 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an RIS.

 

LEI: 549300BNS685UXH4JI75

 

Date: 1 October 2019

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

&

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From:

1 April 2019

To:

31 September 2019

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 ordinary shares of 10 pence

LTIP: 102,714 ordinary shares of 10 pence

MIP: 770,393 ordinary shares of 10 pence

EIP: 1,541,128 ordinary shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 0 ordinary shares of 10 pence

EIP: 0 ordinary shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 237,176 ordinary shares of 10 pence

EIP: 429,828 ordinary shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 ordinary shares of 10 pence

LTIP: 102,714 ordinary shares of 10 pence

MIP: 533,217 ordinary shares of 10 pence

EIP: 1,111,300 ordinary shares of 10 pence

         

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Stock Option Plan ("SOP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2019

-

-

792,700

Blocklisting return on 01/10/2019

 

 

 

 

Block Listing Six Monthly Return

 

Long Term Incentive Plan ("LTIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2019

-

-

102,714

Blocklisting return on 01/10/2019

 

Block Listing Six Monthly Return

Management Incentive Plan ("MIP")

Date

Block

Listing

Shares

Issued

 Balance

 (Headroom)

Notes

 

01/04/2019

 

0

0

770,393

Blocklisting return on 01/04/2019

16/04/2019

0

548

769,845

 

09/05/2019

0

1,633

768,212

 

13/05/2019

0

654

767,558

 

16/05/2019

0

1,323

766,235

 

21/05/2019

0

391

765,844

 

23/05/2019

0

919

764,925

 

24/05/2019

0

209,869

555,056

 

30/05/2019

0

2,540

552,516

 

14/06/2019

0

2,713

549,803

 

19/06/2019

0

5,952

543,851

 

03/07/2019

0

418

543,433

 

24/07/2019

0

3,012

540,421

 

09/08/2019

0

664

539,757

 

02/09/2019

0

3,467

536,290

 

09/09/2019

0

1,979

534,311

 

16/09/2019

0

1,094

533,217

 

01/10/2019

0

0

533,217

Blocklisting Return on 01/10/2019

 

 

 

Block Listing Six Monthly Return

 

Executive Incentive Plan ("EIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2019

0

0

1,541,128

Blocklisting return on 01/04/2019

16/04/2019

0

309,686

1,231,442

 

29/04/2019

0

13,666

1,217,776

 

30/04/2019

0

11,803

1,205,973

 

03/05/2019

0

22,241

1,183,732

 

09/05/2019

0

28,818

1,154,914

 

10/05/2019

0

7,524

1,147,390

 

05/06/2019

0

8,629

1,138,761

 

19/06/2019

0

6,538

1,132,223

 

03/07/2019

0

9,729

1,122,494

 

27/09/2019

0

11,194

1,111,300

 

01/10/2019

0

0

1,111,300

Blocklisting return on 01/10//2019

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRUGGGGUUPBGCG

Quick facts: Hikma Pharmaceuticals Plc

Price: 1902

Market: AIM
Market Cap: £4.61 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE